Pharmacokinetics and Safety of Tedizolid after Single and Multiple Intravenous/Oral Sequential Administrations in Healthy Chinese Subjects.

[1]  Y. Zhang,et al.  Proportions of Staphylococcus aureus and Methicillin-Resistant Staphylococcus aureus in Patients with Surgical Site Infections in Mainland China: A Systematic Review and Meta-Analysis , 2015, PloS one.

[2]  Yan Bai,et al.  Thrombocytopenia in Patients Receiving Prolonged Linezolid May be Caused by Oxidative Stress , 2015, Clinical Drug Investigation.

[3]  A. Shorr,et al.  Analysis of the Phase 3 ESTABLISH Trials of Tedizolid versus Linezolid in Acute Bacterial Skin and Skin Structure Infections , 2014, Antimicrobial Agents and Chemotherapy.

[4]  D. Nathwani,et al.  Pan-European early switch/early discharge opportunities exist for hospitalized patients with methicillin-resistant Staphylococcus aureus complicated skin and soft tissue infections. , 2014, Clinical microbiology and infection : the official publication of the European Society of Clinical Microbiology and Infectious Diseases.

[5]  S. Flanagan,et al.  Pharmacokinetics of Tedizolid in Subjects with Renal or Hepatic Impairment , 2014, Antimicrobial Agents and Chemotherapy.

[6]  S. Flanagan,et al.  Absorption, Distribution, Metabolism, and Excretion of the Novel Antibacterial Prodrug Tedizolid Phosphate , 2014, Drug Metabolism and Disposition.

[7]  G. Moran,et al.  Tedizolid for 6 days versus linezolid for 10 days for acute bacterial skin and skin-structure infections (ESTABLISH-2): a randomised, double-blind, phase 3, non-inferiority trial. , 2014, The Lancet. Infectious diseases.

[8]  Jan V Hirschmann,et al.  Practice guidelines for the diagnosis and management of skin and soft tissue infections: 2014 update by the Infectious Diseases Society of America. , 2014, Clinical infectious diseases : an official publication of the Infectious Diseases Society of America.

[9]  S. Flanagan,et al.  Single- and Multiple-Dose Pharmacokinetics and Absolute Bioavailability of Tedizolid , 2014, Pharmacotherapy.

[10]  S. Flanagan,et al.  Pharmacokinetics of Tedizolid Following Oral Administration: Single and Multiple Dose, Effect of Food, and Comparison of Two Solid Forms of the Prodrug , 2013, Pharmacotherapy.

[11]  Tianming Li,et al.  Current status of Staphylococcus aureus infection in a central teaching hospital in Shanghai, China , 2013, BMC Microbiology.

[12]  Anita F. Das,et al.  Tedizolid phosphate vs linezolid for treatment of acute bacterial skin and skin structure infections: the ESTABLISH-1 randomized trial. , 2013, JAMA.

[13]  M. Grant,et al.  Skin and soft tissue concentrations of tedizolid (formerly torezolid), a novel oxazolidinone, following a single oral dose in healthy volunteers. , 2012, International journal of antimicrobial agents.

[14]  B. Cao,et al.  Antimicrobial resistance trends among 5608 clinical Gram-positive isolates in China: results from the Gram-Positive Cocci Resistance Surveillance program (2005-2010). , 2012, Diagnostic microbiology and infectious disease.

[15]  D. Nicolau,et al.  Pulmonary Disposition of Tedizolid following Administration of Once-Daily Oral 200-Milligram Tedizolid Phosphate in Healthy Adult Volunteers , 2012, Antimicrobial Agents and Chemotherapy.

[16]  S. Cosgrove,et al.  Erratum: Staphylococcus aureus infections in adults and children (Clinical Infectious Diseases (2011) 52:3 (e18-e55)) , 2011 .

[17]  Ping Shen,et al.  Epidemiology and characteristics of antimicrobial resistance in China. , 2011, Drug resistance updates : reviews and commentaries in antimicrobial and anticancer chemotherapy.

[18]  Sara E Cosgrove,et al.  Clinical practice guidelines by the infectious diseases society of america for the treatment of methicillin-resistant Staphylococcus aureus infections in adults and children. , 2011, Clinical infectious diseases : an official publication of the Infectious Diseases Society of America.

[19]  G. Corey,et al.  Phase 2, Randomized, Double-Blind, Dose-Ranging Study Evaluating the Safety, Tolerability, Population Pharmacokinetics, and Efficacy of Oral Torezolid Phosphate in Patients with Complicated Skin and Skin Structure Infections , 2010, Antimicrobial Agents and Chemotherapy.

[20]  D. Nathwani,et al.  Health economic issues in the treatment of drug-resistant serious Gram-positive infections. , 2009, The Journal of infection.

[21]  B. Franklin,et al.  A new approach to treatment of resistant gram-positive infections: potential impact of targeted IV to oral switch on length of stay , 2006, BMC infectious diseases.